Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans

mBio

Volumn 7, Issue 3, 2016, Pages

  Upadhya, Rajendra ^a   Lam, Woei C ^a   Maybruck, Brian ^a   Specht, Charles A ^b   Levitz, Stuart M ^b   Lodge, Jennifer K ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; FUNGUS VACCINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; AMIDASE; CHITIN DEACETYLASE; CYTOKINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CDA DELTA1DELTA2DELTA3 STRAIN; CONTROLLED STUDY; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; FLOW CYTOMETRY; FUNGAL STRAIN; FUNGAL VIRULENCE; INFECTION PREVENTION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE CELL ANALYSIS; SURVIVAL; TH1 CELL; WILD TYPE; ANIMAL; BIOSYNTHESIS; CELL WALL; CELLULAR IMMUNITY; CHEMISTRY; CRYPTOCOCCUS NEOFORMANS; GENETICS; HEAT; IMMUNOLOGY; LUNG; MICROBIOLOGY; MUTATION;

AMIDOHYDROLASES; ANIMALS; CELL WALL; CHITOSAN; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOKINES; FUNGAL VACCINES; HOT TEMPERATURE; IMMUNITY, CELLULAR; LUNG; MICE; MUTATION; TH1 CELLS;

EID: 84979021134     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00547-16     Document Type: Article

References (68)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, ChillerTM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530. http://dx.doi.org/10.1097/QAD.0b013e328322ffac.
2. Byrnes EJ, III, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, May RC, Heitman J. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 6: e1000850. http://dx.doi.org/10.1371/journal.ppat.1000850.
3. Byrnes EJ III, Bartlett KH, Perfect JR, Heitman J. 2011. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect 13: 895-907. http://dx.doi.org/10.1016/j.micinf.2011.05.009.
4. Johnson MD, Perfect JR. 2010. Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep 4: 87-95. http://dx.doi.org/10.1007/s12281-010-0018-6.
5. Krysan DJ. 2015. Toward improved anti-cryptococcal drugs: novel molecules and repurposed drugs. Fungal Genet Biol 78: 93-98. http://dx.doi.org/10.1016/j.fgb.2014.12.001.
6. Smith KD, Achan B, Huppler Hullsiek K, McDonald T, Okagaki LH, Akampurira A, Rhein JR, Meya DB, Boulware DR, Nielsen K, ASTROCM/COAT Team. 2015. Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother 59: 7197-7204. http://dx.doi.org/10.1128/AAC.01299-15.
7. Olszewski MA, Zhang Y, Huffnagle GB. 2010. Mechanisms of cryptococcal virulence and persistence. Future Microbiol 5: 1269-1288. http://dx.doi.org/10.2217/fmb.10.93.
8. Coelho C, Bocca AL, Casadevall A. 2014. The intracellular life of Cryptococcus neoformans. Annu Rev Pathol 9: 219-238. http://dx.doi.org/10.1146/annurev-pathol-012513-104653.
9. Kronstad JW, Attarian R, Cadieux B, Choi J, D’Souza CA, Griffiths EJ, Geddes JM, Hu G, Jung WH, Kretschmer M, Saikia S, Wang J. 2011. Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat Rev Microbiol 9: 193-203. http://dx.doi.org/10.1038/nrmicro2522.
10. Cauley LK, Murphy JW. 1979. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun 23: 644-651.
11. + T cells. J Exp Med 173: 793-800. http://dx.doi.org/10.1084/jem.173.4.793.
12. Datta K, Pirofski LA. 2006. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res 6: 525-536. http://dx.doi.org/10.1111/j.1567-1364.2006.00073.x.
13. Rodrigues ML, Travassos LR, Miranda KR, Franzen AJ, Rozental S, de Souza W, Alviano CS, Barreto-Bergter E. 2000. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect Immun 68: 7049-7060. http://dx.doi.org/10.1128/IAI.68.12.7049-7060.2000.
14. Rosas AL, Nosanchuk JD, Casadevall A. 2001. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun 69: 3410-3412. http://dx.doi.org/10.1128/IAI.69.5.3410-3412.2001.
15. Nosanchuk JD, Rosas AL, Casadevall A. 1998. The antibody response to fungal melanin in mice. J Immunol 160: 6026-6031.
16. Maitta RW, Datta K, Lees A, Belouski SS, Pirofski LA. 2004. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect Immun 72: 196-208. http://dx.doi.org/10.1128/IAI.72.1.196-208.2004.
17. Levitz SM, Huang H, Ostroff GR, Specht CA. 2015. Exploiting fungal cell wall components in vaccines. Semin Immunopathol 37: 199-207. http://dx.doi.org/10.1007/s00281-014-0460-6.
18. Specht CA, Lee CK, Huang H, Tipper DJ, Shen ZT, Lodge JK, Leszyk J, Ostroff GR, Levitz SM. 2015. Protection against experimental Cryptococcosis following vaccination with glucan particles containing Cryptococcus alkaline extracts. mBio 6: e01905-15. http://dx.doi.org/10.1128/mBio.01905-15.
19. Wormley FL, Jr., Perfect JR, Steele C, Cox GM. 2007. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun 75: 1453-1462. http://dx.doi.org/10.1128/IAI.00274-06.
20. Wozniak KL, Ravi S, Macias S, Young ML, Olszewski MA, Steele C, Wormley FL. 2009. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 4: e6854. http://dx.doi.org/10.1371/journal.pone.0006854.
21. Wozniak KL, Young ML, Wormley FL, Jr. 2011. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol 18: 717-723. http://dx.doi.org/10.1128/CVI.00036-11.
22. Rella A, Mor V, Farnoud AM, Singh A, Shamseddine AA, Ivanova E, Carpino N, Montagna MT, Luberto C, Del Poeta M. 2015. Role of sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. Front Microbiol 6: 836. http://dx.doi.org/10.3389/fmicb.2015.00836.
23. Watanabe T, Ito T, Goda HM, Ishibashi Y, Miyamoto T, Ikeda K, Taguchi R, Okino N, Ito M. 2015. Sterylglucoside catabolism in Cryptococcus neoformans with endoglycoceramidase-related protein 2 (EGCrP2), the first steryl-beta-glucosidase identified in fungi. J Biol Chem 290: 1005-1019. http://dx.doi.org/10.1074/jbc.M114.616300.
24. Zhai B, Wozniak KL, Masso-Silva J, Upadhyay S, Hole C, Rivera A, Wormley FL, Jr., Lin X. 2015. Development of protective inflammation and cell-mediated immunity against Cryptococcus neoformans after exposure to hyphal mutants. mBio 6: e01433-15. http://dx.doi.org/10.1128/mBio.01433-15.
25. Baker LG, Specht CA, Lodge JK. 2011. Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans. Eukaryot Cell 10: 1264-1268. doi: http://dx.doi.org/10.1128/EC.05138-11.
26. Baker LG, Specht CA, Donlin MJ, Lodge JK. 2007. Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. Eukaryot Cell 6: 855-867. doi: http://dx.doi.org/10.1128/EC.00399-06.
27. Cain JA, Deepe GS, Jr. 2000. Interleukin-12 neutralization alters lung inflammation and leukocyte expression of CD80, CD86, and major histocompatibility complex class II in mice infected with Histoplasma capsulatum. Infect Immun 68: 2069-2076. http://dx.doi.org/10.1128/IAI.68.4.2069-2076.2000.
28. Root RK, Dale DC. 1999. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 179(Suppl 2): S342-S352. http://dx.doi.org/10.1086/513857.
29. Deepe GS, Jr., McGuinness M. 2006. Interleukin-1 and host control of pulmonary histoplasmosis. J Infect Dis 194: 855-864. http://dx.doi.org/10.1086/506946.
30. Chaturvedi AK, Wormley FL, Jr. 2013. Cryptococcus antigens and immune responses: implications for a vaccine. Expert Rev Vaccines 12: 1261-1272. http://dx.doi.org/10.1586/14760584.2013.840094.
31. Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. 2011. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infect Immun 79: 1915-1926. http://dx.doi.org/10.1128/IAI.01270-10.
32. Murdock BJ, Teitz-Tennenbaum S, Chen GH, Dils AJ, Malachowski AN, Curtis JL, Olszewski MA, Osterholzer JJ. 2014. Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infection. J Immunol 193: 4107-4116. http://dx.doi.org/10.4049/jimmunol.1400650.
33. Baaten BJ, Li CR, Deiro MF, Lin MM, Linton PJ, Bradley LM. 2010. CD44 regulates survival and memory development in Th1 cells. Immunity 32: 104-115. http://dx.doi.org/10.1016/j.immuni.2009.10.011.
34. Angkasekwinai P, Sringkarin N, Supasorn O, Fungkrajai M, Wang YH, Chayakulkeeree M, Ngamskulrungroj P, Angkasekwinai N, Pattanapanyasat K. 2014. Cryptococcus gattii infection dampens Th1 and Th17 responses by attenuating dendritic cell function and pulmonary chemokine expression in the immunocompetent hosts. Infect Immun 82: 3880-3890. http://dx.doi.org/10.1128/IAI.01773-14.
35. Ngamskulrungroj P, Chang Y, Roh J, Kwon-Chung KJ. 2012. Differences in nitrogen metabolism between Cryptococcus neoformans and C. gattii, the two etiologic agents of cryptococcosis. PLoS One 7: e34258. http://dx.doi.org/10.1371/journal.pone.0034258.
36. Rhodes JC, Wicker LS, Urba WJ. 1980. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun 29: 494-499.
37. Carroll SF, Lafferty EI, Flaczyk A, Fujiwara TM, Homer R, Morgan K, Loredo-Osti JC, Qureshi ST. 2012. Susceptibility to progressive Cryptococcus neoformans pulmonary infection is regulated by loci on mouse chromosomes 1 and 9. Infect Immun 80: 4167-4176. http://dx.doi.org/10.1128/IAI.00417-12.
38. Shourian M, Flaczyk A, Angers I, Mindt BC, Fritz JH, Qureshi ST. 2015. The Cnes2 locus on mouse chromosome 17 regulates host defense against cryptococcal infection through pleiotropic effects on host immunity. Infect Immun 83: 4541-4554. http://dx.doi.org/10.1128/IAI.00697-15.
39. Herring AC, Falkowski NR, Chen GH, McDonald RA, Toews GB, Huffnagle GB. 2005. Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells. Infect Immun 73: 39-49. http://dx.doi.org/10.1128/IAI.73.1.39-49.2005.
40. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, Kunkel SL, Strieter RM. 1996. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157: 4529-4536.
41. Huffnagle GB, Chen GH, Curtis JL, McDonald RA, Strieter RM, Toews GB. 1995. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol 155: 3507-3516.
42. Noverr MC, Phare SM, Toews GB, Coffey MJ, Huffnagle GB. 2001. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun 69: 2957-2963. http://dx.doi.org/10.1128/IAI.69.5.2957-2963.2001.
43. Vecchiarelli A, Retini C, Pietrella D, Monari C, Tascini C, Beccari T, Kozel TR. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1beta secretion from human monocytes. Infect Immun 63: 2919-2923.
44. Decken K, Köhler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, Gately MK, Alber G. 1998. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 66: 4994-5000.
45. Hoag KA, Lipscomb MF, Izzo AA, Street NE. 1997. IL-12 and IFNgamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 17: 733-739. http://dx.doi.org/10.1165/ajrcmb.17.6.2879.
46. Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. 2010. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog 6: e1000661. http://dx.doi.org/10.1371/journal.ppat.1000661.
47. Guo C, Chen M, Fa Z, Lu A, Fang W, Sun B, Chen C, Liao W, Meng G. 2014. Acapsular Cryptococcus neoformans activates the NLRP3 inflammasome. Microbes Infect 16: 845-854. http://dx.doi.org/10.1016/j.micinf.2014.08.013.
48. Caffrey AK, Lehmann MM, Zickovich JM, Espinosa V, Shepardson KM, Watschke CP, Hilmer KM, Thammahong A, Barker BM, Rivera A, Cramer RA, Obar JJ. 2015. IL-1alpha signaling is critical for leukocyte recruitment after pulmonary Aspergillus fumigatus challenge. PLoS Pathog 11: e1004625. http://dx.doi.org/10.1371/journal.ppat.1004625.
49. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178. http://dx.doi.org/10.1038/nm.2028.
50. Wüthrich M, LeBert V, Galles K, Hu-Li J, Ben-Sasson SZ, Paul WE, Klein BS. 2013. Interleukin 1 enhances vaccine-induced antifungal T-helper 17 cells and resistance against Blastomyces dermatitidis infection. J Infect Dis 208: 1175-1182. http://dx.doi.org/10.1093/infdis/jit283.
51. Doyle HA, Murphy JW. 1997. MIP-1alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol 61: 147-155.
52. Olszewski MA, Huffnagle GB, Traynor TR, McDonald RA, Cook DN, Toews GB. 2001. Regulatory effects of macrophage inflammatory protein 1alpha/CCL3 on the development of immunity to Cryptococcus neoformans depend on expression of early inflammatory cytokines. Infect Immun 69: 6256-6263. http://dx.doi.org/10.1128/IAI.69.10.6256-6263.2001.
53. + T cells during a pulmonary Cryptococcus neoformans infection. J Immunol 155: 4790-4797.
54. Kawakami K, Kinjo Y, Uezu K, Yara S, Miyagi K, Koguchi Y, Nakayama T, Taniguchi M, Saito A. 2001. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol 167: 6525-6532. http://dx.doi.org/10.4049/jimmunol.167.11.6525.
55. Guillot L, Carroll SF, Homer R, Qureshi ST. 2008. Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection. Infect Immun 76: 4745-4756. http://dx.doi.org/10.1128/IAI.00341-08.
56. Chiller T, Farrokhshad K, Brummer E, Stevens DA. 2002. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. Med Mycol 40: 21-26. http://dx.doi.org/10.1080/mmy.40.1.21.26.
57. Huffnagle GB, Boyd MB, Street NE, Lipscomb MF. 1998. IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 160: 2393-2400.
58. Cheng PY, Sham A, Kronstad JW. 2009. Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neoformans. Infect Immun 77: 4284-4294. http://dx.doi.org/10.1128/IAI.00628-09.
59. Chaturvedi AK, Weintraub ST, Lopez-Ribot JL, Wormley FL, Jr. 2013. Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses. Proteomics 13: 3429-3441. http://dx.doi.org/10.1002/pmic.201300213.
60. Reese TA, Liang HE, Tager AM, Luster AD, Van Rooijen N, Voehringer D, Locksley RM. 2007. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447: 92-96. http://dx.doi.org/10.1038/nature05746.
61. Wagener J, Malireddi RK, Lenardon MD, Köberle M, Vautier S, Mac-Callum DM, Biedermann T, Schaller M, Netea MG, Kanneganti TD, Brown GD, Brown AJ, Gow NA. 2014. Fungal chitin dampens inflammation through IL-10 induction mediated byNOD2and TLR9 activation. PLoS Pathog 10: e1004050. h t t p: //d x. d o i. o r g /1 0. 1 3 7 1 /journal.ppat.1004050.
62. Wiesner DL, Specht CA, Lee CK, Smith KD, Mukaremera L, Lee ST, Lee CG, Elias JA, Nielsen JN, Boulware DR, Bohjanen PR, Jenkins MK, Levitz SM, Nielsen K. 2015. Chitin recognition via chitotriosidase promotes pathologic type-2 helper T cell responses to cryptococcal infection. PLoS Pathog 11: e1004701. h t t p: //d x. d o i. o r g /1 0. 1 3 7 1 /journal.ppat.1004701.
63. Alvarez FJ. 2014. The effect of chitin size, shape, source and purification method on immune recognition. Molecules 19: 4433-4451. http://dx.doi.org/10.3390/molecules19044433.
64. Da Silva CA, Chalouni C, Williams A, Hartl D, Lee CG, Elias JA. 2009. Chitin is a size-dependent regulator of macrophage TNF and IL-10 production. J Immunol 182: 3573-3582. http://dx.doi.org/10.4049/jimmunol.0802113.
65. Bueter CL, Lee CK, Wang JP, Ostroff GR, Specht CA, Levitz SM. 2014. Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol 192: 5943-5951. http://dx.doi.org/10.4049/jimmunol.1301695.
66. O’Meara TR, Norton D, Price MS, Hay C, Clements MF, Nichols CB, Alspaugh JA. 2010. Interaction of Cryptococcus neoformans Rim101 and protein kinase A regulates capsule. PLoS Pathog 6: e1000776. http://dx.doi.org/10.1371/journal.ppat.1000776.
67. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H. 2013. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse Lung. Am J Respir Cell Mol Biol 49: 503-510. http://dx.doi.org/10.1165/rcmb.2013-0086MA.
68. Groom JR, Luster AD. 2011. CXCR3 in T cell function. Exp Cell Res 317: 620-631. http://dx.doi.org/10.1016/j.yexcr.2010.12.017.